SEOUL -- GI Biome, a microbiome-based drug developer in South Korea, has started administering GB-X01, an anti-colorectal cancer candidate, to patients in the first clinical trial in South Korea. Through the test, the company aims to confirm the safety, drug tolerance, and composition variation of intestinal microorganisms before and after administration.

Original article: GI Biome starts clinical trial of colorectal cancer treatment candidate 'GB-X01'